Because the Mcl-1 and Wnt/β-catenin signaling pathways were molecularly identified as regulatory targets of PCDH7, we discovered a combination of the Mcl-1 inhibitor S63845 and ABT-263 as a novel chemotherapy treatment option for PCDH7-high colorectal cancer. Here, PCDH7 is linked to colorectal cancer.